{
    "clinical_study": {
        "@rank": "79016", 
        "arm_group": {
            "arm_group_label": "Malignant Glioma patients", 
            "description": "This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, except Dr. Eli Diamond's patients and respective caregivers, will be screened for eligibility and willingness to participate in the study."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to learn more about patients with brain tumors understanding of\n      their disease and their communication with their physician. Ultimately, we hope to use these\n      findings to improve communication between patients and their doctors."
        }, 
        "brief_title": "Prognostic Awareness and Patient-Physician Communication in Malignant Glioma", 
        "condition": "Malignant Glioma", 
        "condition_browse": {
            "mesh_term": "Glioma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patient Inclusion Criteria\n\n          -  Age greater than or equal to 18\n\n          -  Diagnosis of any WHO grade III or IV glioma\n\n          -  Admitted to the inpatient Neurology service\n\n          -  Has had at least one outpatient visit with a neuro-oncologist at MSKCC Fluent in\n             English\n\n        Caregiver Inclusion Criteria\n\n          -  Age greater than or equal to 18\n\n          -  Identified by the patient as a relative, friend, or partner with whom he or she has a\n             significant relationship and who provides him or her physical or emotional\n             assistance.\n\n          -  The patient has himself or herself agreed to participate in this study\n\n        Exclusion Criteria:\n\n        Patient Exclusion Criteria\n\n          -  A patient will be excluded if the Glasgow Coma Scale is less than 15, with one\n             exception: if the score is 14 because of disorientation to date only, as evaluated in\n             the verbal assessment, the patient is eligible to participate. The patient must be\n             oriented to self, age, place, and year, and month.\n\n          -  Aphasia precluding comprehension and verbalization of consent to participate\n\n          -  Is a patient of Dr. Eli Diamond\n\n          -  Patients who cannot verbally demonstrate their understanding of the risks, benefits,\n             and alternatives to participating in the study. This evaluation will take place for\n             otherwise eligible and willing participants, and it will be performed by the NP or MD\n             clinician who is obtaining informed consent and will be documented in the medical\n             record.\n\n        Caregiver Exclusion Criteria\n\n          -  No eligible caregivers who can complete the brief assessment in person will be\n             excluded"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Participants will be recruited from the inpatient Neurology service."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02023346", 
            "org_study_id": "13-253"
        }, 
        "intervention": {
            "arm_group_label": "Malignant Glioma patients", 
            "intervention_name": "surveys and cognitive tests", 
            "intervention_type": "Behavioral"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Patient-Physician Communication", 
            "Brain cancer", 
            "13-253"
        ], 
        "lastchanged_date": "December 23, 2013", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": {
            "contact": {
                "last_name": "Eli Diamond, MD", 
                "phone": "212-639-7576"
            }, 
            "contact_backup": {
                "last_name": "Lisa DeAngelis, MD", 
                "phone": "212-639-7123"
            }, 
            "facility": {
                "address": {
                    "city": "New Yori", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Memoral Sloan Kettering Cancer Center"
            }, 
            "investigator": {
                "last_name": "Eli Diamond, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prognostic Awareness and Patient-Physician Communication in Malignant Glioma", 
        "overall_contact": {
            "last_name": "Eli Diamond, MD", 
            "phone": "212-639-7576"
        }, 
        "overall_contact_backup": {
            "last_name": "Lisa DeAngelis, MD", 
            "phone": "212-639-7123"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Eli Diamond, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Prognostic awareness (PA) will be measured using the Chochinov Prognostic Awareness Scale. This scale classifies patients into three categories of awareness: full, limited, or no awareness.", 
            "measure": "measure prognostic awareness", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02023346"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}